Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models

Matthew Squires(Novartis (United States)), Neil T. Thompson(University of Cambridge)

Molecular Cancer Therapeutics

July 16, 2011

10.1158/1535-7163.mct-11-0426

Cited by 32

Related Papers

The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models

|Molecular Cancer Therapeutics|2012|59

Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

|Annals of Oncology|2016|46

Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with <i>BRAF</i> V600–mutant melanoma.

|Journal of Clinical Oncology|2017|6

Abstract CT087: Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) with <i>BRAF</i> V600E/K-mutant melanoma in the COMBAT trial

|Cancer Research|2018|1

Supplementary Figure Legend from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models

|Unknown|2023|0